Form 8-K - Current report:
SEC Accession No. 0001140361-22-027135
Filing Date
2022-07-27
Accepted
2022-07-27 16:30:26
Documents
12
Period of Report
2022-07-21
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K brhc10040035_8k.htm   iXBRL 8-K 23256
  Complete submission text file 0001140361-22-027135.txt   157305

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA btx-20220721.xsd EX-101.SCH 3871
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE btx-20220721_lab.xml EX-101.LAB 22546
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btx-20220721_pre.xml EX-101.PRE 16049
6 EXTRACTED XBRL INSTANCE DOCUMENT brhc10040035_8k_htm.xml XML 4091
Mailing Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220
Business Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220 (212) 582-1199
Brooklyn ImmunoTherapeutics, Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 221111393
SIC: 2834 Pharmaceutical Preparations